Page 68 - 《中国药房》2020年22期
P. 68

·药物经济学·

        英夫利昔单抗治疗溃疡性结肠炎的成本-效用分析                                                       Δ


        陈文煦    1,2* ,晨 迪 ,沈爱宗 (1.安徽中医药大学药学院,合肥 230012;2.中国科学技术大学附属第一医院/
                                   1,2 #
                         1,2
        安徽省立医院药剂科,合肥 230001)

        中图分类号 R956;R574.62          文献标志码 A          文章编号     1001-0408(2020)22-2750-07
        DOI   10.6039/j.issn.1001-0408.2020.22.11
        摘   要   目的:评价英夫利昔单抗治疗溃疡性结肠炎的经济性。方法:计算机检索中国知网、万方数据知识服务平台、维普期刊资
        源整合服务平台、PubMed、Embase和 Cochrane图书馆等数据库,检索时限均为建库起至 2019 年 10 月 16 日。收集英夫利昔单抗
        (试验组)对比常规药物(对照组)治疗溃疡性结肠炎的随机对照试验,通过Meta分析比较两组患者的疗效和安全性;采用成本-效
        用分析法分析其经济性,并进行单因素敏感性分析和概率敏感性分析。结果:Meta分析结果显示,使用英夫利昔单抗治疗的双盲
        试验亚组患者的临床反应率[RR=1.97,95%CI(1.64,2.36),P<0.000 01]和临床缓解率[RR=3.19,95%CI(1.83,5.57),P<0.000 1]均
        显著高于接受常规治疗的对照组。两种方案的不良反应发生率比较差异无统计学意义[RR=0.76,95%CI(0.54,1.06),P=0.10]。
        试验组方案的增量成本-效用比为348 243.88元/质量调整生命年(QALY),明显高于患者的意愿支付阈值(212 676元);敏感性分
        析支持上述结果。结论:在当前我国医疗保障水平下,与常规疗法相比,英夫利昔单抗用于治疗溃疡性结肠炎患者的经济性欠佳。
        关键词 溃疡性结肠炎;英夫利昔单抗;Meta分析;成本-效用分析

        Cost-utility Analysis of Infliximab in the Treatment of Ulcerative Colitis
                                1,2
                                               1,2
                     1,2
        CHEN Wenxu ,CHEN Di ,SHEN Aizong (1. College of Pharmacy,Anhui University of Chinese Medicine,
        Hefei 230012,China;2. Dept. of Pharmacy,the First Affiliated Hospital of USTC/Anhui Provincial Hospital,
        Hefei 230001,China)
        

             breast cancer following STAT3 suppression[J]. PLoS One,  apoptosome[J]. Exp Cell Res,2012,318(11):1213-1220.
             2013. DOI:10.1371/journal.pone.0065896.        [21]  PEREIRA MA,HERREN-FREUND SL,BRITT AL,
        [16]  TRACEY J,SUSAN J. Signal transducer and activator of  et al. Effect of coadministration of phenobarbital sodium
             transcription(STAT)signalling and T-cell lymphomas[J].  on N-nitrosodiethylamine-induced gamma-glutamyltrans-
             Immunology,2005,114(3):301-312.                     ferase-positive foci and hepatocellular carcinoma in rats[J].
        [17]  LIU YW,WANG LJ,WU YP,et al. Pterostilbene exerts   J Natl Cancer Inst,1984,72(7):741-744.
             antitumor activity against human osteosarcoma cells by in-  [22]  ARIF M,VEDAMURTHY BM,CHOUDHARI R,et al.
             hibiting the JAK2/STAT3 signaling pathway[J]. Toxicolo-  Nitric oxide-mediated histone hyperacetylation in oral can-
             gy,2013,304(3):120-131.                             cer:target for a water-soluble HAT inhibitor,CTK7A[J].
        [18]  DU W,HONG J,WANG YC,et al. Inhibition of JAK2/     Chem Biol,2010,17(8):903-913.
             STAT3 signalling induces colorectal cancer cell apoptosis  [23]  EBELT J,NEID M,TANNAPFEL A,et al. Prognostic sig-
             via mitochondrial pathway[J]. J Cell Mol Med,2012,16  nificance of proliferation markers in hepatocellular carci-
             (8):1878-1888.                                      noma(HCC)[J]. Zentralbl Chir,2000,125(7):597-601.
        [19]  GROSS A,MCDONNELL JM,KORSMEYER SJ. Bcl-2      [24]  KUWANO H,SUMIYOSHI K,NOZOE T,et al. The
             family members and the mitochondria in apoptosis[J].  prognostic significance of the cytophotometric DNA con-
             Genes Dev,1999,13(4):1899-1911.                     tent and its relationship with the argyrophilic nucleolar or-
        [20]  WRSTLE ML,LAUSSMANN MA,REHM M. The cen-            ganizer regions(AgNOR)and proliferating cell nuclear an-
             tral role of initiator caspase-9 in apoptosis signal transduc-  tigen(PCNA)in oesophageal cancer[J]. Eur J Surg Oncol,
             tion and the regulation of its activation and activity on the  1995,21(4):368-373.
            Δ 基金项目:国家卫生健康委员会药政司政府购买服务课题(No.                 [25]  KELLOFF GJ,LIEBERMAN R,STEELE VE,et al. Che-
        药政〔2018〕购2号)                                             moprevention of prostate cancer:concepts and strate-
            *硕士研究生。研究方向:临床药学与肿瘤药理学。E-mail:                       gies[J]. Eur Urol,1999,35(5/6):342-350.
        cwx19960306@163.com                                              (收稿日期:2020-06-14  修回日期:2020-10-17)
            # 通信作者:主任药师,硕士生导师。研究方向:临床药学与医院                                                       (编辑:段思怡)
        药事管理。E-mail:1649441800@qq.com


        ·2750 ·  China Pharmacy 2020 Vol. 31 No. 22                                 中国药房    2020年第31卷第22期
   63   64   65   66   67   68   69   70   71   72   73